You are on page 1of 1

Zambia

| High HIV burden | Tuberculosis profile


Population 2012 14 million
Estimates of TB burden * 2012 Number (thousands)
Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.9 (1.47.7) 28 (9.855)
Mortality (HIV+TB only) 7.6 (6.28.9) 54 (4463)
Prevalence (includes HIV+TB) 55 (2890) 388 (197642)
Incidence (includes HIV+TB) 60 (5466) 427 (385470)
Incidence (HIV+TB only) 35 (3239) 251 (226276)
Case detection, all forms (%) 68 (6275)
TB case notifications 2012
New cases (%) Retreatment cases (%)
Smear-positive 12 645 (33) Relapse 1 857 (29)
Smear-negative 17 050 (44) Treatment after failure 213 (3)
Smear-unknown / not done Treatment after default 509 (8)
Extrapulmonary 9 174 (24) Other 3 829 (60)
Other
Total new 38 869 Total retreatment 6 408
Other (history unknown)
Total new and relapse 40 726 Total cases notified 45 277
New cases Smear-positive
Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.7 1.4 1.3
Age < 15 321 1 637 1 374
Laboratories 2012
Smear (per 100 000 population)
Culture (per 5 million population)
Drug susceptibility testing (per 5 million population)
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)
New smear-positive and/or culture-positive 88
Is rifampicin used
throughout treatment for
new patients? Yes
New smear-negative/extrapulmonary
Retreatment
TB/HIV 2012 Number (%)
TB patients with known HIV status 39 543 (87)
HIV-positive TB patients 24 309 (61)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 22 614 (93)
HIV-positive TB patients on antiretroviral therapy (ART) 14 471 (60)
HIV-positive people screened for TB
HIV-positive people provided with IPT
Estimates of MDR-TB burden 2012* New Retreatment
% of TB cases with MDR-TB 0.33 (0.041.2) 8.1 (4.114)
MDR-TB cases among notified pulmonary
TB cases
98 (12350) 520 (260900)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB
Laboratory-confirmed MDR-TB cases 80
Patients started on MDR-TB treatment 97
Financing TB control 2013
National TB programme budget (US$ millions) 39
% Funded domestically 27%
% Funded internationally 76%
% Unfunded <1%
***
(Rate per 100 000 population per year)
1990 1994 1998 2002 2006 2010
0
50
100
150
___ Mortality (excludes HIV+TB)
(Rate per 100 000 population)
1990 1994 1998 2002 2006 2010
0
400
800
1200
___ Prevalence
(Rate per 100 000 population per year)
1990 1994 1998 2002 2006 2010
0
400
800
__ Notifications ___ Incidence
___ Incidence (HIV+TB only)
Treatment success rate (%)
1995 1997 1999 2001 2003 2005 2007
65
75
85
__ New smear-positive and/or culture-positive
__New smear-negative/extrapulmonary __
Retreatment
(Number of patients)
2003 2005 2007 2009 2011
0
10000
20000
30000
__ HIV-positive TB patients
__on CPT __on ART
Total budget (US$ millions)
2009 2010 2011 2012 2013
0
10
20
30
40
__ Funded domestically __ Funded internationally
__ Unfunded
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
* Ranges represent uncertainty intervals Generated: 2014-09-22 Data: www.who.int/tb/data